Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY. Luo FR, et al. Among authors: mcglinchey k. Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27. Cancer Chemother Pharmacol. 2008. PMID: 18301894 Free article.
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ, Camuso A, Clark J, Fager K, Gullo-Brown J, Hunt JT, Inigo I, Kan D, Koplowitz B, Lee F, McGlinchey K, Qian L, Ricca C, Rovnyak G, Traeger S, Tokarski J, Williams DK, Wu LI, Zhao Y, Manne V, Bhide RS. Lombardo LJ, et al. Among authors: mcglinchey k. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1895-9. doi: 10.1016/j.bmcl.2005.02.004. Bioorg Med Chem Lett. 2005. PMID: 15780629
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY. Luo FR, et al. Among authors: mcglinchey k. Cancer Chemother Pharmacol. 2005 Nov;56(5):455-64. doi: 10.1007/s00280-005-1022-3. Epub 2005 Jun 10. Cancer Chemother Pharmacol. 2005. PMID: 15947929
Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Wong TW, Kramer RA, Wild R, Lee FY. Luo FR, et al. Among authors: mcglinchey k. Clin Cancer Res. 2005 Aug 1;11(15):5558-65. doi: 10.1158/1078-0432.CCR-05-0368. Clin Cancer Res. 2005. PMID: 16061873
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R. Lee FY, et al. Among authors: mcglinchey k. Cancer Chemother Pharmacol. 2009 Jan;63(2):201-12. doi: 10.1007/s00280-008-0727-5. Epub 2008 Mar 19. Cancer Chemother Pharmacol. 2009. PMID: 18350296
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.
Shan W, Balog A, Quesnelle C, Gill P, Han WC, Norris D, Mandal S, Thiruvenkadam R, Gona KB, Thiyagarajan K, Kandula S, McGlinchey K, Menard K, Wen ML, Rose A, White R, Guarino V, Shen DR, Cvijic ME, Ranasinghe A, Dai J, Zhang Y, Wu DR, Mathur A, Rampulla R, Trainor G, Hunt JT, Vite GD, Westhouse R, Lee FY, Gavai AV. Shan W, et al. Among authors: mcglinchey k. Bioorg Med Chem Lett. 2015 May 1;25(9):1905-9. doi: 10.1016/j.bmcl.2015.03.038. Epub 2015 Mar 23. Bioorg Med Chem Lett. 2015. PMID: 25857941
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C, Franks R, Leyland R, Mulgrew K, McGlinchey K, Brown L, Dovedi SJ, Koopmann JO, Durham NM, Cheng X, Jin H, Eyles J, Wilkinson RW, Carroll D. Harper J, et al. Among authors: mcglinchey k. Mol Cancer Ther. 2021 Sep;20(9):1723-1734. doi: 10.1158/1535-7163.MCT-20-0902. Epub 2021 Jun 17. Mol Cancer Ther. 2021. PMID: 34224361 Free PMC article.
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Goldman JW, et al. Among authors: mcglinchey k. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016. Clin Cancer Res. 2022. PMID: 35699623
23 results